Can Financial Economics Cure Cancer?

<jats:title>Abstract</jats:title><jats:p>Funding for early-stage biomedical innovation has become more difficult to secure at the same time that medical breakthroughs seem to be occurring at ever increasing rates. One explanation for this counterintuitive trend is that increasing s...

Full description

Bibliographic Details
Main Author: Lo, Andrew W
Other Authors: Sloan School of Management
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2022
Online Access:https://hdl.handle.net/1721.1/144205
_version_ 1826207625798221824
author Lo, Andrew W
author2 Sloan School of Management
author_facet Sloan School of Management
Lo, Andrew W
author_sort Lo, Andrew W
collection MIT
description <jats:title>Abstract</jats:title><jats:p>Funding for early-stage biomedical innovation has become more difficult to secure at the same time that medical breakthroughs seem to be occurring at ever increasing rates. One explanation for this counterintuitive trend is that increasing scientific knowledge can actually lead to greater economic risk for investors in the life sciences. While the Human Genome Project, high-throughput screening, genetic biomarkers, immunotherapies, and gene therapies have made a tremendously positive impact on biomedical research and, consequently, patient lives, they have also increased the cost and complexity of the drug development process, causing many investors to shift their assets to more attractive investment opportunities. This suggests that new business models and financing strategies can be used to reduce the risk and increase the attractiveness of biomedical innovation so as to bring new and better therapies to patients faster.</jats:p>
first_indexed 2024-09-23T13:52:29Z
format Article
id mit-1721.1/144205
institution Massachusetts Institute of Technology
language English
last_indexed 2024-09-23T13:52:29Z
publishDate 2022
publisher Springer Science and Business Media LLC
record_format dspace
spelling mit-1721.1/1442052023-02-03T20:52:22Z Can Financial Economics Cure Cancer? Lo, Andrew W Sloan School of Management <jats:title>Abstract</jats:title><jats:p>Funding for early-stage biomedical innovation has become more difficult to secure at the same time that medical breakthroughs seem to be occurring at ever increasing rates. One explanation for this counterintuitive trend is that increasing scientific knowledge can actually lead to greater economic risk for investors in the life sciences. While the Human Genome Project, high-throughput screening, genetic biomarkers, immunotherapies, and gene therapies have made a tremendously positive impact on biomedical research and, consequently, patient lives, they have also increased the cost and complexity of the drug development process, causing many investors to shift their assets to more attractive investment opportunities. This suggests that new business models and financing strategies can be used to reduce the risk and increase the attractiveness of biomedical innovation so as to bring new and better therapies to patients faster.</jats:p> 2022-08-03T17:57:20Z 2022-08-03T17:57:20Z 2021 2022-08-03T17:51:42Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/144205 Lo, Andrew W. 2021. "Can Financial Economics Cure Cancer?." Atlantic Economic Journal, 49 (1). en 10.1007/S11293-021-09704-7 Atlantic Economic Journal Creative Commons Attribution 4.0 International license https://creativecommons.org/licenses/by/4.0/ application/pdf Springer Science and Business Media LLC Springer
spellingShingle Lo, Andrew W
Can Financial Economics Cure Cancer?
title Can Financial Economics Cure Cancer?
title_full Can Financial Economics Cure Cancer?
title_fullStr Can Financial Economics Cure Cancer?
title_full_unstemmed Can Financial Economics Cure Cancer?
title_short Can Financial Economics Cure Cancer?
title_sort can financial economics cure cancer
url https://hdl.handle.net/1721.1/144205
work_keys_str_mv AT loandreww canfinancialeconomicscurecancer